Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10022
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHo, Prahlad Wen
dc.contributor.authorReutens, David Cen
dc.contributor.authorPhan, Thanh Gen
dc.contributor.authorWright, Peter Men
dc.contributor.authorMarkus, Romeshen
dc.contributor.authorIndra, Indraen
dc.contributor.authorYoung, Dennisen
dc.contributor.authorDonnan, Geoffrey Aen
dc.date.accessioned2015-05-15T23:20:44Z
dc.date.available2015-05-15T23:20:44Z
dc.date.issued2005-11-03en
dc.identifier.citationStroke; A Journal of Cerebral Circulation 2005; 36(12): 2742-4en
dc.identifier.govdoc16269640en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10022en
dc.description.abstractOne of the reasons for the failure of trials of neuroprotection in stroke may be the lack of white matter (WM) protection. However, whether patients entered into typical neuroprotection trials have WM involved in the ischemic process is unknown. We studied patients who were enrolled in neuroprotection trials at our center and used a neuroimaging coregistration approach to determine whether final infarcts involved WM and, if so, in what proportion. We also aimed to provide the first in vivo volume distribution of gray matter (GM) and WM in normal stroke-aged brains.Patients enrolled in trials of neuroprotection had late computed tomography or magnetic resonance scans coregistered in standard stereotaxic coordinate space after segmentation of symptomatic cerebral infarcts. These were then superimposed on a probabilistic map of GM and WM, which was developed from age-matched normal controls in whom GM and WM volumes were assessed.Forty-two patients (mean age, 73.7+/-10.5 years) were studied from 6 trials of neuroprotection. WM formed 41.7% of the brain volume in 37 control subjects (mean age, 73.5+/-8.4 years). In the segmented infarcts, WM comprised a median of 49% (interquartile range, 36.5 to 77.9) of the infarct volume. Ninety-five percent of infarcts had some involvement of WM tracts.WM occupies approximately 42% by volume of the normal stroke-aged brain. Patients entered into typical trials of neuroprotection may have significant WM volumes involved in the ischemic process, thus providing a rationale for the development of neuroprotectants for this compartment.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherBrain Mappingen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherMagnetic Resonance Imagingen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherMyelin Sheath.drug effects.pathology.radiographyen
dc.subject.otherNeuroprotective Agents.pharmacologyen
dc.subject.otherOrgan Sizeen
dc.subject.otherReference Valuesen
dc.subject.otherStroke.pathology.prevention & control.radiographyen
dc.subject.otherTomography, X-Ray Computeden
dc.titleIs white matter involved in patients entered into typical trials of neuroprotection?en
dc.typeJournal Articleen
dc.identifier.journaltitleStrokeen
dc.identifier.affiliationNational Stroke Research Institute, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia en
dc.identifier.doi10.1161/01.STR.0000189748.52500.a7en
dc.description.pages2742-4en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16269640en
dc.type.austinJournal Articleen
local.name.researcherDonnan, Geoffrey A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.